When Will Retatrutide Be Available in the UK? MHRA Timeline 2026

Retatrutide is currently the most anticipated peptide compound in the UK — but when will it actually be available on prescription? This guide covers the current regulatory status, Phase 3 trial timelines, and what UK researchers need to know about accessing retatrutide now.

Current Status — Phase 3 Trials

As of April 2026, retatrutide (LY3437943, developed by Eli Lilly) is in Phase 3 clinical trials under the TRIUMPH programme. Phase 3 trials evaluate safety and efficacy in larger populations across multiple conditions including obesity, type 2 diabetes, and MASH (metabolic-associated steatohepatitis).

Projected MHRA Approval Timeline

What Will Retatrutide Cost on Prescription in the UK?

Based on Mounjaro pricing as a comparator, brand-name retatrutide (if approved) would likely cost £800–£1,500 per month on private prescription initially. NHS availability, if approved via NICE, would follow the NHS formulary process — typically 12–24 months post-MHRA approval.

Why Researchers Can't Wait Until 2027

Academic and institutional research into retatrutide's mechanisms, receptor interactions, and metabolic effects is happening now — not in 2027. Understanding the compound's pharmacodynamics, dose-response relationships and mechanistic pathways is precisely the work that precedes and informs therapeutic approval.

Accessing Retatrutide for Research in 2026

Research-grade retatrutide is available now from Alluvi Healthcare in the UK for qualified in vitro laboratory research applications. Our current stock uses batch AR0763RT4, independently verified by Janoshik Analytical at 99.38% purity. The Retatrutide 40mg Pen (4 doses of 10mg) is available from £195 per box with full COA documentation.